-
-
Charcot-Marie-Tooth (CMT) UK virtual conference
-
17th May 2021
-
Posted in Courses & Conferences
- Virtual conference from CMT UK (Charcot-Marie-Tooth), 21-22 May 2021
-
-
Merck Announces New Data Supporting Continued Use of MAVENCLAD (Cladribine Tablets) During the COVID-19 Pandemic
-
6th May 2021
-
Posted in Industry News
- Mavenclad news from Merck
-
-
Encephalitis Society – Call for Abstracts
-
5th May 2021
-
Posted in Course & Conference Previews
- Call for Abstracts from The Encephalitis Society
-
-
Real-world data in Parkinson’s disease patients with motor fluctuations assesses the clinical utility of Ongentys® (opicapone)
-
29th Apr 2021
-
Posted in Industry News,Sponsored Feature
- Heinz Reichmann
-
-
NECTAR Conference 2020
-
22nd Apr 2021
-
Posted in Courses & Conferences
- Sophie Skidmore, Venkat Pisupati and Shaline Fazal
-
-
NICE recommends Novartis’ Kesimpta®▼ (ofatumumab) for patients living with relapsing remitting multiple sclerosis (RRMS)
-
21st Apr 2021
-
Posted in Industry News
- Industry news from Novartis
-
-
The self-report version and digital format of the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS) for Long Covid or Post-COVID syndrome assessment and monitoring
-
13th Apr 2021
-
Posted in Clinical Review Article,COVID-19 Articles,Rehabilitation Articles
- A self-report version (and digital format) of the C19-YRS tool for completion by patients with Long Covid.
-
-
Stroke scholarships at UCL – 31st May deadline
-
6th Apr 2021
-
Posted in Course & Conference Previews,Industry News
- * New deadline* Apply by 31st May
-
-
PCN-101 (R-ketamine) for depressive disorders
-
2nd Apr 2021
-
Posted in Industry News
- News from Perception Neuroscience and Otsuka Pharmaceutical Co., Ltd
-
-
Novartis receives EU approval for Kesimpta® (ofatumumab), self-administered, targeted B-cell therapy for adult patients with relapsing MS
-
1st Apr 2021
-
Posted in Industry News
- News from Novartis
